Syntara Limited · ASX:SNT
Syntara — Hong Kong Ignite Investment Summit (October 2025)
17 slides from Syntara's conference presentation, Oct 15, 2025
Slide 1: Hong Kong Ignite Investment Summit
For personal use only Hong Kong Ignite Investment Summit Gary Phillips, CEO 15 October 2025
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT For personal use only This document contains risks, uncertainties and other forward-looking statements, factors, many of which are including statements beyond our control, and which concerning Syntara’s future may cause actual results to financial position, plans, and the d
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only Australian-founded Backed by Multiple shots on Funded into 2027 with clinical stage specialist healthcare goal from additional near term data to drive drug developer. investors – Phase 2, Phase 1 and value over the next 47% institutional. preclinical asset
Slide 4: Shareholders & Cash
SHAREHOLDERS & CASH Financial Information (ASX: SNT) Share Price & Volume - YTD Share price – 10 October 2025 $0.034 Close 0.1 For personal use only Market cap A$55.5m 0.09 0.08 Proforma cash balance (30 Jun 2025)1 A$20.7m 0.07 0.06 0.05 Enterprise value A$34.8m 0.04 Note 1: 0.03 Proforma cash of $2
Slide 5: Myelofibrosis
MYELOFIBROSIS A rare type of bone marrow cancer that disrupts the body’s normal production of blood cells KEY FACTS Myelofibrosis characterised by a build up of scar tissue • Orphan disease affects ~15 in 1m people (fibrosis) in bone marrow and abnormal proliferation of worldwide (USA ~ 20,000 patie
Slide 6: Myelofibrosis: Limited treatment options currently
MYELOFIBROSIS Limited treatment options currently Current standard of care (SoC): JAK inhibitors Amsulostat For personal use only In contrast to SoC, amsulostat intervenes at the Key• Class Factsof drugs used in the management of splenomegaly source, clearing fibrosis from the bone marrow and (enlar
Slide 7: Lysyl Oxidases in Myelofibrosis
LYSYL OXIDASES IN MYELOFIBROSIS Amsulostat designed to improve the bone marrow microenvironment Lysyl oxidase gene family upregulated in the bone marrow (BM) of myelofibrosis patients; increased lysyl oxidase activity adversely impacts BM health in several ways* For personal use only Structural Effe
Slide 8: Lysyl Oxidases in Myelofibrosis: Amsulostat
LYSYL OXIDASES IN MYELOFIBROSIS Amsulostat designed to improve the bone marrow microenvironment Lysyl oxidase gene family upregulated in the bone marrow (BM) of myelofibrosis patients; increased lysyl oxidase activity adversely impacts BM health in several ways* For personal use only Amsulostat Amsu
Slide 9: Aims/Methods: MF-101 Add-on to RUX
AIMS/METHODS MF-101 Add-on to RUX (NCT4676529) Add-on phase aimed to further evaluate the safety and efficacy of amsulostat (200 mg BID) in patients with MF on stable background regimens of ruxolitinib (RUX) over a 52-week period For personal use only STUDY POPULATION DESIGN ENDPOINTS ▪ DIPSS Int-2/
Slide 10: Baseline Characteristics
BASELINE CHARACTERISTICS Heterogenous population Characteristic N=16 with a high disease burden For personal use only Age, median (range), years 71 (46-82) Sex, male, n (%) 7 (44) Study now complete Time since MF diagnosis, median (range), months 60 (7–135) • 13 patients (pts) reached 12 weeks Diagn
Slide 11: Total Symptom Score
TOTAL SYMPTOM SCORE Reduction at W24 Additional reduction past W24 73% (8/11) of patients achieved TSS50 at Week 24 or beyond * Pt continued past W38 # Pt completed W52 and study For personal use only Baseline TSS 37 10 52# 32 11* 18# 22# 45# 23# 10# 19# Symptom relief continues 0 for patients: TSS
Slide 12: Spleen Volume Reduction
SPLEEN VOLUME REDUCTION 44% (4/9) of patients achieved SVR25 at Week 24 or beyond For personal use only Improved spleen volume reduction: • At Week 24, 7/9 (78%) evaluable patients* experienced stable or reduced spleen volume with no increases in RUX dose. • 4/9 (44%) evaluable patients achieved SVR
Slide 13: Positive Top Line Phase 2a Data Highlights
POSITIVE TOP LINE PHASE 2A DATA HIGHLIGHTS AMSULOSTAT’S POTENTIAL IN MYELOFIBROSIS For personal use only Improvements of 50% or Meaningful spleen Of the 7 patients Next stage of amsulostat more in total symptom volume reductions that completed 52 clinical development and score (TSS50) (SVR) were obs
Slide 14: Syntara Appoints Global Myelofibrosis Experts
SYNTARA APPOINTS GLOBAL MYELOFIBROSIS EXPERTS TO SUPPORT AMSULOSTAT DEVELOPMENT For personal use only Strategic Advisors to Myelofibrosis Clinical Syntara Board, Haematology Advisory Board ▪ Dr Adam Craig ▪ Professor Claire Harrison Former CEO of CTI BioPharma Corp, responsible for Professor of Myel
Slide 15: Strong Interest in MF Assets from Strategics
STRONG INTEREST IN MF ASSETS FROM STRATEGICS Target / Acquiror / / / / For personal use only DATE OF ANNOUNCEMENT DEC-2024 FEB-2024 JUNE-2023 JULY-2022 Drug Name Elritercept Pelabresib Pacritinib Momelotinib Lead Indication / MDS and MF Myelofibrosis Myelofibrosis Myelofibrosis Phase (at transaction
Slide 16: Poised to Deliver Near Term Value
POISED TO DELIVER NEAR TERM VALUE TARGET DRUG INDICATION PARTNERS PHASE 1 PHASE 2 NEWS FLOW HEALTHY Q4 2025 H1 2026 H2 2026 PATIENTS For personal use only PARTICIPANTS FDA approved development plan Myelofibrosis and partner engagement Amsulostat Phase 1c interim Pan-LOX High Risk Phase 2 (SNT-5505)
Slide 17: Contact
For personal use only Syntara Limited ABN 75 082 811 630 Gary Phillips Chief Executive Officer www.syntaraTX.com.au LinkedIn Twitter Logo WhiteOnBlue gary.phillips@syntaraTX.com.au
Syntara — Hong Kong Ignite Investment Summit (October 2025) on 6ix